Remicade® (Infliximab) Receives Positive Opinion From CHMP In Europe for Treatment of Ulcerative Colitis in Pediatric ...

MSD today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the use of REMICADE® in the treatment of severely active ulcerative colitis in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who ...

Celgene Reports Record Fourth Quarter and Full Year 2011 Operating and Financial Results

Celgene Corporation reported Non-GAAP net product sales of $1,241 million for the fourth quarter of 2011, a 21 percent increase from the same period in 2010. Non-GAAP net income for the fourth quarter of 2011 increased 38 percent to $473 million compared to $343 million in the fourth quarter of 2010.

Protalix Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network ...

CARMIEL, Israel -- Protalix BioTherapeutics, Inc. (NYSE Amex:PLX) , announced today that new clinical data on taliglucerase alfa will be presented at the 8th Annual Meeting of the Lysosomal Disease Network: ...

CORRECTING and REPLACING Remicade® (Infliximab) Receives Positive Opinion From CHMP In Europe for Treatment of ...

Please replace the release dated January 20, 2012 with the following corrected version due to several revisions.

Celgene Corporation Announces 2012 Financial Outlook and Reviews 2011 Achievements

Celgene Corporation today reviewed 2011 achievements and provided its outlook for 2012 at the JPMorgan 30th Annual Healthcare Conference.